Claims

1. A mucosal patch comprising:

a drug-containing layer comprising electrospun fibers, wherein the electrospun fibers comprise:

a drug substance;

20% to 45% by weight polyvinylpyrrolidone,

20% to 45% by weight ammonio methacrylate copolymer type B; and

15% to 60% by weight polyethylene oxide;

and

a backing layer comprising poly(caprolactone).

2. The mucosal patch according to claim 1, wherein the drug substance is a corticosteroid.

3. The mucosal patch according to claim 1, wherein the drug substance is clobetasol propionate.

4. The mucosal patch according to claim 1 or 2, wherein the amount of ammonio methacrylate copolymer type B in the electrospun fibers is 25% to 45% by weight.

5. The mucosal patch according to any one of claims 1-4, wherein the weight ratio of polyvinylpyrrolidone to ammonio methacrylate copolymer type B is 0.7 to 1..

6. The mucosal patch according to any one of claims 1-5, wherein the amount of polyvinylpyrrolidone and ammonio methacrylate copolymer type B in the electrospun fibers is 50% to 85% by weight.

7. The mucosal patch according to any one of claims 1-6, wherein the weight average molecular weight of the polyvinylpyrrolidone is 900,000 Da to 3,000,000 Da.

8. The mucosal patch according to any one of claims 1-7, wherein the weight average molecular weight of the polyvinylpyrrolidone is 1,500,000 Da.

9. The mucosal patch according to any one of claims 1-7, wherein the ammonio methacrylate copolymer type B is a copolymer of ethyl acrylate, methyl methacrylate, and trimethylammonioethyl methacrylate chloride in a molar ratio of 1: 2: 0.1.

10. The mucosal patch according to any one of claims 1-9, wherein the ammonio methacrylate copolymer type B is a copolymer of ethyl acrylate, methyl methacrylate, and trimethylammonioethyl methacrylate chloride having a weight average molar mass of 32,000 g/mol.

11. The mucosal patch according to any one of claims 1-10, wherein the average molecular weight of the polyethylene oxide is 100,000 to 4,000,000.

12. The mucosal patch according to any one of claims 11, wherein the amount of polyethylene oxide in the electrospun fibers is 15% to 50% by weight.

13. The mucosal patch according to any one of claims 1-12, wherein the amount of polyethylene oxide in the electrospun fibers is 50% by weight.

14. The mucosal patch according to any one of claims 1-13, wherein the weight ratio of polyethylene oxide to polyvinylpyrrolidone and ammonio methacrylate copolymer type B is 0.8 to 1.

15. The mucosal patch according to any one of claims 1-14, wherein the poly(caprolactone) comprises melted electrospun poly(caprolactone) fibers.

16. The mucosal patch according to any one of claims 1-15, wherein the backing layer further comprises a pigment.

17. A kit comprising the mucosal patch of any one of claims 1-16.

18. The mucosal patch according to any of claims 1-16 for use in the treatment of diseases of the oral or vaginal cavity.